CD Pharmaceuticals AB
CD Pharmaceuticals AB is the Swedish arm of CD Pharma Group, an independent pharmaceutical distribution and services platform that represents small and medium-sized drug makers across Nordic, Baltic, UK, Irish, Swiss and Russian markets via a Milano-anchored certified warehouse and partner warehouse network.
- Company typePrivate
- Founded2009
- HeadquartersUppsala, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingServices
What CD Pharmaceuticals AB does
CD Pharmaceuticals AB is the Swedish operating entity of CD Pharma Group, an independent, privately held international pharmaceutical distribution and services platform. Founded in Italy in 2009 and expanded to Uppsala in 2011 and Bissone (Switzerland) in 2017, the group operates three offices and reaches 11+ countries across the Nordic, Baltic, UK, Ireland, Switzerland and Russia. Its core business combines distribution of partner-marketed pharmaceutical brands — primarily Carnitene, Synacthen, Syntocinon and Zaditen on behalf of AlfaSigma, and Natulan, Revcovi and Chenodeoxycholic Acid Leadiant on behalf of Leadiant Biosciences Ltd — with fee-based agency representation, regulatory affairs, product registration and pharmacovigilance services for small and medium-sized pharmaceutical producers.
The platform's technical backbone is a fully certified pharmaceutical warehouse in Milano used as the central logistics hub, complemented by independent partner warehouses in each target market. Distribution is executed either directly from Milano via logistics partners or via local warehouses, with the group explicitly positioned as a turnkey market-entry solution covering market research, regulatory work, registration, pharmacovigilance and lifecycle commercialization. The model is hybrid: transaction-based revenue on distributed product sales (agency/distributor economics) layered with professional-services revenue from regulatory, registration and pharmacovigilance engagements.
Customers are small and medium-sized pharmaceutical producers (including those originating from Russian, European and Asian markets) that lack local infrastructure to enter regulated European or Russian markets; the group also targets producers of new or unregistered products in rare-disease therapeutic areas. Pricing and commercial terms are not publicly disclosed and are negotiated per client per market. The group is wholly independent, with no public listing, no disclosed funding rounds, no M&A activity, no leadership changes on record, and a reported headcount of 1-10 across the entire organization.
CD Pharmaceuticals AB firmographics
Firmographics- Name
- CD Pharmaceuticals AB
- Legal name
- CD Pharmaceuticals AB
- Website
- https://cdpharmagroup.one
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- CD Pharmaceuticals AB is the Swedish arm of CD Pharma Group, an independent pharmaceutical distribution and services platform that represents small and medium-sized drug makers across Nordic, Baltic, UK, Irish, Swiss and Russian markets via a Milano-anchored certified warehouse and partner warehouse network.
- Ownership category
- akta.pro rank
CD Pharmaceuticals AB industry classification
Industry- Product category
- Pharmaceutical Distribution Services
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (4242)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
Keywords
Where CD Pharmaceuticals AB is headquartered
LocationHeadquarters
- HQ city
- Uppsala
- HQ country
- Sweden
- HQ region
- Europe
Offices4 records
Markets served
CD Pharmaceuticals AB business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Distribution and sales of pharmaceutical products: Generates revenue by acting as distributor/agent selling pharmaceutical products (Carnitene, Synacthen, Syntocinon, Zaditen, Natulan, Revcovi, Chenodeoxycholic Acid Leadiant) on behalf of authorization holders (AlfaSigma, Leadiant Biosciences Ltd) across Nordic, Baltic, UK, Ireland, Switzerland and Russian markets via its own Milano warehouse and partner warehouses.
- Agency representation and sales services: Operates as a local agent/representation office for pharmaceutical producers, earning commissions or agency margins on sales booked in target markets.
- Regulatory, registration and pharmacovigilance services: Provides fee-based market research, product registration, regulatory work and pharmacovigilance services to pharmaceutical manufacturers seeking market entry or lifecycle support.
- Warehousing and logistics services: Offers certified warehousing, transport and logistics services from the Milano facility and via partner warehouses to pharmaceutical clients.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels3 records
CD Pharmaceuticals AB product offering
Product offeringCore offering
CD Pharmaceuticals AB operates as an independent international pharmaceutical distribution and services platform, representing and distributing partner-marketed specialty pharmaceutical products (Carnitene, Synacthen, Syntocinon, Zaditen, Natulan, Revcovi, Chenodeoxycholic Acid Leadiant) across Nordic, Baltic, UK, Ireland, Switzerland and Russian markets. The company offers a turnkey service portfolio spanning representation office, agency, market research and analysis, sales and distribution, pharmacovigilance, product registration, regulatory work, warehousing and logistics, leveraging its own certified pharmaceutical warehouse in Milano, Italy as the central hub.
Product overview
CD Pharmaceuticals AB (CD Pharma Group) operates as an international, independent pharmaceutical distribution and services platform rather than a single unified product. The offering combines distribution of partner-marketed pharmaceutical brands — including Carnitene, Synacthen, Syntocinon, Zaditen, Natulan, Revcovi, and Chenodeoxycholic Acid Leadiant (under the "CD Pharma Excellent Health" line) — with a service portfolio spanning representation office, agency, market research and analysis, sales and distribution, pharmacovigilance, product registration, regulatory work, warehousing, logistics, introduction of new products, revitalization of old products, and search for new products. These service modules wrap the distributed product portfolio, enabling CD Pharmaceuticals AB to provide turnkey market entry and ongoing commercialization for pharmaceutical manufacturers across Nordic, Baltic, UK, Ireland, Swiss and Russian markets from its Uppsala (Sweden), Milan (Italy) and Bissone (Switzerland) offices.
Differentiator
Problem solved
Functional benefit
Brands
- CD Pharma Excellent Health: Distinct sub-brand used for the group's pharmaceutical product portfolio (antineoplastics, gastrointestinal, hormones, antihistamines).
Products and services
- Natriuran (Natulan) 50mg 50 Tab Natriuran (procarbazine) 50mg tablets, distributed by CD Pharmaceuticals AB. Marketing authorisation held by Leadiant Biosciences Ltd, country of origin Germany. Used as an antineoplastic agent.
- Revcovi Leadiant Revcovi (elapegademase-lvlr) distributed by CD Pharmaceuticals AB. Marketing authorisation held by Leadiant Biosciences Ltd, country of origin USA. Used in antineoplastic/immunomodulator therapy.
- Chenodeoxycholic Acid Leadiant 250mg Chenodeoxycholic acid 250mg, distributed by CD Pharmaceuticals AB. Marketing authorisation held by Leadiant Biosciences Ltd, country of origin UK. Used in gastrointestinal and metabolic disorders.
- Carnitene product range Carnitene (L-carnitine) portfolio distributed by CD Pharmaceuticals AB in multiple formulations: 1g drinking ampoules (10x1g), 200mg/ml injection (5x5ml), 30% oral solution (20ml), 1g chewing tablets (10 count), and 330mg tablets (90 count). Marketing authorisation held by AlfaSigma, country of origin Italy. Used for gastrointestinal and metabolic indications.
- Synacthen ampoule range Synacthen (tetracosactide) distributed by CD Pharmaceuticals AB in two formats: Depot/Retard 1mg/1ml liquid ampoules (10x1) and 0.25mg/1ml liquid ampoules across Sweden, Ireland and Denmark. Marketing authorisation held by AlfaSigma. Used as a pituitary/hypothalamic hormone diagnostic and therapeutic agent.
- Syntocinon ampoule and nasal spray range Syntocinon (oxytocin) distributed by CD Pharmaceuticals AB in liquid ampoules (5IU/1ml and 10IU/1ml) and nasal spray (40IU/ml 5ml) formats across Sweden, Finland, Ireland, Denmark and Norway. Marketing authorisation held by AlfaSigma. Used as a pituitary/hypothalamic hormone for obstetric and lactation indications.
- Zaditen tablet and syrup range Zaditen (ketotifen) distributed by CD Pharmaceuticals AB as 0.02% syrup 300ml and 1mg tablets (60 count) in Ireland and as 1mg/5ml syrup 300ml and 1mg tablets (60 count) in the UK. Marketing authorisation held by AlfaSigma. Used as a systemic antihistamine.
- CD Pharma Excellent Health branded product line CD Pharma Excellent Health is the branded product line under which CD Pharmaceuticals AB distributes its portfolio of partner-marketed pharmaceuticals across Nordic, Baltic, UK, Ireland, Switzerland and Russian markets.
- Pharmaceutical market entry and distribution service Turnkey market-entry and distribution service covering market research and analysis, product registration, regulatory work, agency representation, sales and distribution, warehousing and logistics. Targeted at small and medium-sized pharmaceutical producers seeking access to Nordic, Baltic, UK, Irish, Swiss and Russian markets.
- Pharmacovigilance and product complaints service Pharmacovigilance service including adverse event reporting and product complaint handling, offered to pharmaceutical producers via a dedicated quality-pv email channel.
- Certified pharmaceutical warehousing and logistics service Certified pharmaceutical warehousing, transport and logistics services operated from the group's own fully certified warehouse in Milano, Italy and via independent partner warehouses across Scandinavia, Switzerland, UK, Ireland and Russia.
Quantifiable outcome
- Combined Nordic coverage of ca 27.5 million population (Sweden, Denmark, Norway, Finland, Iceland)
- +1 more outcomes
Companies that use CD Pharmaceuticals AB
Customer profileSegments3 records
Ideal customer profiles3 records
CD Pharmaceuticals AB technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CD Pharmaceuticals AB partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- AlfaSigmacoreAlfaSigma is the marketing authorization holder for the majority of CD Pharma Group's distributed portfolio, including Carnitene (oral, injection, chewing-tablet and drinking ampoule formulations), Synacthen, Syntocinon and Zaditen products marketed across Sweden, Denmark, Norway, Finland, Ireland and the UK.
- Leadiant Biosciences LtdcoreLeadiant Biosciences Ltd is the marketing authorization holder for CD Pharma's antineoplastic/immunomodulator and gastrointestinal products including Natulan 50MG (Germany), Revcovi Leadiant (USA) and Chenodeoxycholic Acid Leadiant 250mg (UK).
- Logistics partners in Nordic/Baltic/Russia/UK/Ireland/SwitzerlandcoreCD Pharma Group works with logistics partners that deliver products either directly from its Milano warehouse or via local warehouses in each market, reaching practically all pharmacies across the network.
- Independent warehouses and local distributors (Nordic & Baltic)coreFinalized agreements with independent warehouses or local distributors covering Sweden, Denmark, Norway, Finland, Iceland, Estonia, Latvia and Lithuania to underpin CD Pharma's distribution network.
Scale indicators5 records
Recent moves8 records
Expansion highlights4 records
CD Pharmaceuticals AB competitors and assessment
Company assessmentBroad incumbents
- Sobi (Swedish Orphan Biovitrum): Swedish-listed rare-disease specialty biopharma company headquartered near Stockholm. Adjacent incumbent with deep Nordic footprint and rare-disease commercialization expertise; not a distributor but a credible partner/competitor in the same orphan-disease Nordic ecosystem.
- Clinigen Group: UK-listed specialty pharma and services group with operations in unlicensed/unregistered medicine supply, clinical trial supply and commercial distribution across multiple regions. Comparable niche focus on unregistered and specialty medicines and multi-jurisdiction commercialization.
- Phoenix Group: One of Europe's largest pharmaceutical distribution groups, headquartered in Germany with extensive wholesale and pre-wholesale operations across continental Europe. Represents the scale incumbent CD Pharma competes alongside or relies on for parts of its network.
- STADA Arzneimittel: German-based European generics and specialty pharma group with broad portfolio across multiple European markets. Comparable in multi-market European distribution and lifecycle management for established or niche molecules.
- Alliance Healthcare: Walgreens Boots Alliance's pharmaceutical wholesale and distribution arm operating across multiple European countries including UK, France, Germany and Nordics. Broader incumbent with overlapping distribution and pharmacy reach that CD Pharma taps into as a partner.
- Norgine: European specialty pharma company focused on gastroenterology and other niche therapeutic areas with its own pan-European commercial infrastructure. Comparable in operating as a specialty pharma company with multi-country European distribution.
Direct peers
- Eurocept Pharmaceuticals: Dutch specialty pharma company providing market entry, registration, distribution and lifecycle services for niche and rare-disease products across Europe. Closely mirrors CD Pharma's turnkey boutique-distributor model and target customer profile.
- Orifarm Group: Danish-headquartered parallel importer and pharma distributor with strong Nordic/Baltic presence and a portfolio of in-licensed and partner-marketed products. Most direct comparable in geography, business model (parallel distribution + agency representation) and target customer segment (small/mid-cap pharma principals seeking European market access).
Emerging players
- Medison Pharma: Israel-based specialty pharma distributor focused on bringing innovative and rare-disease therapies to markets including Europe and CIS. Comparable niche focus on unregistered/orphan products and multi-market access for small/mid-cap pharma producers.
- Desma Healthcare: Specialty pharma company supporting niche and orphan product commercialization across European markets. Similar boutique model targeting small/mid-cap pharma principals seeking European market access.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
CD Pharmaceuticals AB social profiles
Digital presenceCD Pharmaceuticals AB financial estimates
Financial estimateRevenue estimate
Valuation estimate
CD Pharmaceuticals AB leadership team
Management profileNumber of profiles
CD Pharmaceuticals AB subsidiaries and ownership
Company hierarchySubsidiaries2 records
CD Pharmaceuticals AB funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CD Pharmaceuticals AB M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CD Pharmaceuticals AB
What does CD Pharmaceuticals AB do?
CD Pharmaceuticals AB operates as an independent international pharmaceutical distribution and services platform, representing and distributing partner-marketed specialty pharmaceutical products (Carnitene, Synacthen, Syntocinon, Zaditen, Natulan, Revcovi, Chenodeoxycholic Acid Leadiant) across Nordic, Baltic, UK, Ireland, Switzerland and Russian markets. The company offers a turnkey service portfolio spanning representation office, agency, market research and analysis, sales and distribution, pharmacovigilance, product registration, regulatory work, warehousing and logistics, leveraging its own certified pharmaceutical warehouse in Milano, Italy as the central hub.
Is CD Pharmaceuticals AB a public or private company?
CD Pharmaceuticals AB is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was CD Pharmaceuticals AB founded?
CD Pharmaceuticals AB was founded in 2009. It employs 1 to 10 people.
Where is CD Pharmaceuticals AB based?
CD Pharmaceuticals AB is headquartered in Uppsala, Sweden, in the Europe region.
How does CD Pharmaceuticals AB make money?
Four revenue lines are on record. Distribution and sales of pharmaceutical products are the primary driver. The others are agency representation and sales services, regulatory, registration and pharmacovigilance services and warehousing and logistics services.
Who are CD Pharmaceuticals AB's main competitors?
Broad incumbents on record are Sobi (Swedish Orphan Biovitrum), Clinigen Group, Phoenix Group, STADA Arzneimittel, Alliance Healthcare and Norgine. Direct peers are Eurocept Pharmaceuticals and Orifarm Group. Emerging players are Medison Pharma and Desma Healthcare.
Does CD Pharmaceuticals AB have an API?
No public API is recorded for CD Pharmaceuticals AB.
What industry is CD Pharmaceuticals AB in?
CD Pharmaceuticals AB's product category is Pharmaceutical Distribution Services. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 424210 and its SIC code is 5122.